Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/11 10:00:55 pm
172.76 USD   +2.96%
12/08 TEVA CONSIDERIN : Bloomberg
12/08 TEVA CONSIDERIN : Bloomberg
12/07 EDITAS MEDICINE : BioCentury - Editas raises $50M follow-on
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on ALLERGAN PLC
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/07 ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
12/07 EDITAS MEDICINE : BioCentury - Editas raises $50M follow-on
12/01 Tech firms tell patent court to ignore Allergan deal with tribe
11/30 ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
11/29DJALLERGAN : Health Care Up on Rotation Out of Tech -- Health Care Roundup
11/29 ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
11/24 ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
11/22 ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
11/21 ALLERGAN : to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conf..
11/21 ALLERGAN : Receives FDA Approval For Use of VRAYLAR cariprazine in the Maintenan..
11/17 ALLERGAN PLC : . (AGN) Shares Bought by Bank Hapoalim BM
11/16 ALLERGAN : to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conf..
11/16 ALLERGAN : Overactive Bladder Causes Significant Burden Regardless of Age Amongs..
11/16 ALLERGAN PLC : ex-dividend day
11/15 ALLERGAN : Receives FDA Approval for Use of VRAYLAR in the Maintenance Treatment..
11/14 ALLERGAN : Overactive Bladder Causes Significant Burden, Regardless of Age Among..
11/14 ALLERGAN : lands FDA approval for schizophrenia drug
11/13 ALLERGAN : to sell a quarter of its Teva stake in first quarter 2018
11/13 Pfizer creates chief operating officer role for Bourla
11/13 ALLERGAN : Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the ..
11/10 Novartis posts eye drug data amid play for Eylea's turf
11/10 AMGEN : And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevac..
11/09 ALLERGAN : Receives Approval for Ozurdex® Dexamethasone Intravitreal Implant 0.7..
11/09 ALLERGAN : Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterin..
11/09 ALLERGAN : UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Cl..
11/08 SEN. HASSAN AND COLLEAGUES TO ALLERG : Monopoly Keeps Price of Drug High, Limits..
11/08 SENATORS TO ALLERGAN CEO : Monopoly Keeps Price of Drug High, Limits Competition
11/08 ALLERGAN : to Present Dynamic Eye Care Data at American Academy of Ophthalmology..
11/07 ALLERGAN : and Regeneron Stumble
11/07 ALLERGAN : UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Cl..
11/07 ALLERGAN : to Present at Credit Suisse 26th Annual Healthcare Conference
11/07 ALLERGAN : Sen. Margaret Wood Hassan (D-NH) News Release
11/07 ALLERGAN : Senators Demand Answers Ahead of House Subcommittee Hearing in Respon..
11/05 LEN BLAVATNIK : Billionaire Blavatnik weighs big share purchase in Teva Pharm - ..
11/03 ALLERGAN : Presented New Phase 3 Data of Ulipristal Acetate in Women
11/03 ALLERGAN : Reports Solid Top Line Execution in Third Quarter 2017 with 11% Incre..
11/02 ALLERGAN : Board of Directors Announces Fourth Quarter 2017 Cash Dividend and In..
11/02 ALLERGAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
11/01 ALLERGAN : to begin selling its 10 percent stake in Teva
11/01 ALLERGAN PLC. (NYSE : AGN) reported earnings of $4.15 per share beating Walls St..
11/01 ALLERGAN : reports 3Q loss on charges, but tops expectations
11/01 ALLERGAN PLC : Results of Operations and Financial Condition, Financial Statemen..
11/01 ALLERGAN : Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Incre..
11/01 ALLERGAN PLC : to Host Earnings Call
10/31 ALLERGAN : Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterin..
10/30 ALLERGAN : Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0...
10/27 ALLERGAN : Board of Directors Announces Fourth Quarter 2017 Cash Dividend and In..
10/26 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/26 COOLSCULPTING : ® Breaks the Ice about Non-Invasive Fat Freezing with Actress De..
10/25 ALLERGAN : to Present Latest Studies of Ulipristal Acetate for Uterine Fibroids ..
10/23 ALLERGAN : to Present Latest Studies of Ulipristal Acetate for Uterine Fibroids ..
10/23 ALLERGAN : Issues Investor FAQ on Federal District Court RESTASIS Patent Decisio..
10/20 ALLERGAN : Imprimis Pharma to take on Allergan's Restasis with cheaper product
10/19 ALLERGAN : Academy of Managed Care Pharmacy AMCP Foundation and Allergan Offered..
10/19 ALLERGAN : Announces that the FDA Accepts New Drug Application for Ulipristal Ac..
10/19 ALLERGAN : to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical..
10/19 ALLERGAN : Announces Settlement on RESTASIS® Cyclosporine Ophthalmic Emulsion 0...
10/19 SYNDAX PHARMACEUTICALS : Expands Pipeline with Exclusive Worldwide License to Al..
10/19 ALLERGAN : Issues Investor FAQ on Federal District Court RESTASIS® Patent Decisi..
10/18 ALLERGAN : ruling casts doubt on tribal patent strategy
10/18 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/18 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/18 ALLERGAN : ruling casts doubt on tribal patent strategy
10/17 Amneal, Impax combine to tackle generic drug pricing pressure
10/16DJALLERGAN : Loses Patent Fight in Federal Court
10/16 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/16 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/16 ALLERGAN : Announces Settlement on RESTASIS 0.05% Patent Litigation with InnoPha..
10/13 ALLERGAN : to Present Data from More Than 20 Abstracts at the 2017 Fall Clinical..
10/12 ALLERGAN : Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) ..
10/12 ALLERGAN : FDA Accepts Supplemental New Drug Application sNDA filing for AVYCAZ®..
10/12 ALLERGAN : To Present New Data From Its Anti-Infectives Portfolio At IDWeek 2017..
10/12 ALLERGAN : Announces that the FDA Accepts New Drug Application for Ulipristal Ac..
1  2  3  4  5  6  7  8  9Next
Financials ($)
Sales 2017 15 894 M
EBIT 2017 7 658 M
Net income 2017 -5 870 M
Debt 2017 24 765 M
Yield 2017 1,66%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,17x
EV / Sales 2018 5,13x
Capitalization 57 457 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 225 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-21.49%57 457
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659